US Patent 11,147,808: What the Claims Cover and How the Landscape Likely Shapes Enforcement
US Drug Patent 11,147,808 is directed to a specific co-administration regimen of bupropion plus dextromethorphan to a dextromethorphan non-poor metabolizer in order to decrease pharmacokinetic variability (the patent’s “fluctuation index”) of dextromethorphan on day 8, relative to a control regimen using 60 mg dextromethorphan alone.
At a practical level, the enforceable scope is driven by three claim pillars:
- Patient/phenotype gate: “non-poor metabolizer” of dextromethorphan.
- Dose and schedule gate: a tightly defined step-up then maintenance dosing schedule over at least day 8.
- Outcome gate: a defined target fluctuation index range and a minimum reduction percentage versus the specified dextromethorphan-alone comparator.
What is the core claim concept (and what must be proven)?
Independent claim 1 (method of decreasing fluctuation index)
Claim 1 requires all of the following elements:
- Method: “decreasing the fluctuation index of dextromethorphan”
- Recipient: “a human being who is a non-poor metabolizer of dextromethorphan”
- Co-administration drug pair: bupropion + dextromethorphan
- Dosing amounts (ranges)
- Bupropion: about 70 mg to 150 mg
- Dextromethorphan: about 30 mg to 60 mg
- Schedule
- Once daily for 3 consecutive days, then
- Twice daily for at least 5 consecutive days
- Day-8 pharmacokinetic targets
- Fluctuation index on day 8 is about 20% to 30%
- Minimum improvement requirement
- Day-8 fluctuation index reduced by at least about 70% versus what would result from:
- 60 mg dextromethorphan alone, once daily for 3 days, then twice daily for at least 5 days
Key proof consequence: A validity or infringement analysis will hinge on whether the accused dosing regimen:
- matches the dose and schedule ranges (including step-up),
- involves non-poor metabolizers,
- yields the claimed day-8 fluctuation index target and the specified reduction vs the comparator.
What specific limitations expand coverage in dependent claims?
Duration limits (claims 2-3, 14)
- Claim 2: co-administer for at least 14 consecutive days
- Claim 3: co-administer for at least 30 consecutive days
- Claim 14: claim 13-specific variant for at least 30 consecutive days
These duration claims matter because they provide additional footholds for enforcement when the accused product is dosed longer than the minimum needed to reach day 8 pharmacokinetics.
Indication tie-ins (claims 4-6, 10-12, 15-17, 21-23)
The patent explicitly links the method to:
- Depression (claims 4, 10, 15, 21)
- Nicotine addiction (claims 5, 11, 16, 22)
- Agitation associated with Alzheimer's disease (claims 6, 12, 17, 23)
Infringement consequence: If the method is practiced in a clinical setting for one of these indications, the claims give a narrative and functional alignment. That said, the real claim hook is still the fluctuation-index PK outcome and dosing parameters.
Salt/formulation specificity and single dosage form (claims 7-9, 18-20, 19-20)
- Claim 7: preferred numeric embodiment
- about 105 mg bupropion HCl (or molar equivalent free base/other salt)
- with about 44 mg to 46 mg dextromethorphan hydrobromide (or molar equivalent)
- dosing schedule matches claim 1 (once daily 3 days, twice daily ≥5 days)
- Claim 8: bupropion + dextromethorphan are the only active agents in a single dosage form
- Claim 9: dextromethorphan is immediate release
A parallel set exists in claims 18-20 (same concept but dependent numbering tied to claim 7 and claim 9).
Coverage consequence: Formulation and IR limitations can narrow infringement for products that do not provide the specific release form or do not co-formulate as a single dosage form with no other actives.
Tighter day-8 fluctuation index ranges (claims 13, 27, 29)
- Claim 13: day-8 fluctuation index about 25% to 28%
- Claim 27: fluctuation index about 30%
- Claim 29: fluctuation index about 28%
These introduce multiple “centers of gravity” within the broader 20%-30% band in claim 1, supporting infringement theories for varying measured outcomes.
PK exposure metrics tied to day 8 (claims 24-26, 28)
- Claim 24: Cmax on day 8 about 158 ng/mL
- Claim 25: Cave on day 8 about 140 ng/mL
- Claim 26: Cmin on day 8 at least 115 ng/mL
- Claim 28: Cmin about 119 ng/mL
- Claim 29 / claim 27 linkage: ties fluctuation index to those concentration constraints
Coverage consequence: These dependent claims can become decisive for literal infringement if the target regimen produces a fluctuation index in range but does not align with the specified Cmax/Cave/Cmin values.
What is the practical claim map (scope-by-scope)?
Drug combination scope
- Mandatory: bupropion + dextromethorphan
- Bupropion dose range: ~70 to 150 mg
- Dextromethorphan dose range: ~30 to 60 mg
- Regimen step-up: once daily for 3 days, then twice daily for at least 5 days
- Phenotype filter: non-poor metabolizer of dextromethorphan
- Outcome: day-8 fluctuation index 20%-30% and ≥70% reduction vs 60 mg dextromethorphan alone
Narrowing embodiments
- Specific salt: bupropion HCl and dextromethorphan hydrobromide (claim 7; claim 18)
- Single dosage form, only actives: bupropion and dextromethorphan (claim 8; claim 19)
- Dextromethorphan IR (claim 9; claim 20)
- Day-8 tighter fluctuation index bands: 25%-28%, 28%, 30% (claims 13, 27, 29)
- Exposure metrics: Cmax, Cave, Cmin targets on day 8 (claims 24-26, 28)
What does this mean for the US patent landscape (how competitors can design around)?
The “design-around” surface is unusually measurement-anchored
Many combination patents focus on composition, indication, or administration route. Here, the independent claim is an outcome-based PK variability reduction measured on day 8 with a defined comparator scenario.
That structure creates design-around pressure along three axes:
- Comparator change (harder to do if the method claim is enforced as written).
- Non-poor metabolizer definition (competitors can try to avoid selecting or treating that phenotype, but real-world labeling and practice patterns matter).
- PK endpoint divergence: even if the dosing pair is used, failing to reach the day-8 fluctuation index targets (or the ≥70% reduction) can avoid literal infringement.
Narrow “single dosage form” and IR limitations increase freedom for alternate product formats
- A competitor using the same actives but:
- with different release form for dextromethorphan (not immediate release), or
- as separate dosage forms,
- or with additional actives in the same dosage form,
can potentially avoid dependent-claim coverage anchored to those constraints.
- However, independent claim 1 does not explicitly require single dosage form or immediate release, so the freedom is mostly for narrowing which claims can be asserted.
Salt-form and exact numeric embodiments create layered infringement risk
If a competitor uses different salt forms or differs meaningfully from the numeric embodiment (claim 7/18), they may avoid dependent claims that recite those salts. Independent claim 1 remains broader because it uses ranges.
How the claim set can support different infringement theories
1) Narrow-literal infringement (best-case for enforcement)
- Use non-poor metabolizers
- Use the specific dosing step-up and maintenance
- Achieve day-8 fluctuation index within the claimed band
- Show ≥70% reduction vs 60 mg dextromethorphan alone
- If possible, match immediate release and single dosage form to capture dependent claims
2) Wider infringement using claim 1
Even if a product differs from dependent-claim constraints (IR, single dosage form, salt), claim 1 still captures the core regimen plus the day-8 fluctuation outcome.
3) Indication-based leverage
The claims list depression, nicotine addiction, and agitation in Alzheimer’s disease. That supports tying the method to real prescribing and labeling narratives, though the operative infringement element is still the PK outcome.
What claim terms will matter most in prosecution and litigation?
“Fluctuation index”
The patent defines an outcome measurement (day-8 fluctuation index) with numeric bands and reductions. Litigation will focus on:
- definition and calculation method used in the patent,
- assay timing consistency,
- how the comparator regimen is modeled or measured.
“Non-poor metabolizer”
This constrains the patient population. Enforcing parties typically align with established phenotyping approaches (e.g., CYP2D6-related metabolizer status), but the claim as provided only states “non-poor metabolizer.”
Day 8 and the comparator
Claim 1 is explicit:
- “fluctuation index of dextromethorphan on the eighth day”
- reduction versus dextromethorphan alone at 60 mg with the same time pattern
Those details make it less useful for generic “same drug, same dosing” arguments that ignore PK endpoint timing.
Patent landscape assessment: likely positioning of US 11,147,808
Based on claim architecture alone, US 11,147,808 is positioned as a method-of-treatment PK-variability reduction patent rather than a conventional polymorph/composition patent. That usually means the landscape includes other patents at the periphery (formulations, dosing for indications, metabolizer-related dosing strategies, or bupropion-dextromethorphan combination intellectual property), but the enforceable center for this specific patent is:
- specific bupropion + dextromethorphan regimen
- in non-poor metabolizers
- achieving day-8 PK variability reduction with specific numeric targets.
Because you provided only the claims and not the patent record metadata (filing dates, assignee, specification definition of fluctuation index, prior art citations, citation graph, or related family members), a full landscape map with competitor identifiers cannot be produced from the available inputs.
Key Takeaways
- US 11,147,808 claims a method with a phenotype gate (“non-poor metabolizer”) and a day-8 PK outcome (“fluctuation index” in a 20%-30% band) achieved by bupropion + dextromethorphan under a step-up dosing schedule.
- Independent claim 1 is outcome-comparator anchored: it requires ≥70% reduction vs a 60 mg dextromethorphan-alone regimen with the same time pattern.
- Dependent claims add enforceable layers for: minimum treatment duration, specific indications, salt forms, single dosage form only actives, immediate release, tighter fluctuation index bands, and day-8 Cmax/Cave/Cmin targets.
- The design-around surface is measurement-driven: avoiding the day-8 fluctuation index target or the comparator-defined reduction is the most direct way to reduce infringement risk.
- Formulation constraints mainly affect dependent coverage; claim 1 remains the broadest capture if dosing and day-8 PK outcome are met.
FAQs
-
Is US 11,147,808 a composition patent or a method patent?
It is a method-of-treatment claim set (method of decreasing fluctuation index via co-administration and outcome limits).
-
Does the claim require a particular day besides day 8?
Claim 1 requires the fluctuation index on day 8. Dependent claims add longer treatment durations (at least 14 or 30 days).
-
What are the key drug dosing constraints?
Bupropion is ~70-150 mg, dextromethorphan is ~30-60 mg, with once daily for 3 days then twice daily for at least 5 days.
-
Can a competitor avoid infringement by changing indication?
Changing indication may avoid dependent indication-linked claims, but claim 1 does not require an indication in the provided text; it still requires the PK outcome and dosing regimen.
-
What is the most defensible design-around lever from these claims?
Achieving a regimen that does not meet the claimed day-8 fluctuation index band or fails to produce the required ≥70% reduction versus the specified comparator regimen.
References
[1] US Patent 11,147,808 (claims as provided by user content).
